People: Hologic Inc (HOLX.OQ)
HOLX.OQ on NASDAQ Stock Exchange Global Select Market
22.64USD
2 Aug 2013
22.64USD
2 Aug 2013
Price Change (% chg)
$-0.22 (-0.96%)
$-0.22 (-0.96%)
Prev Close
$22.86
$22.86
Open
$22.98
$22.98
Day's High
$22.98
$22.98
Day's Low
$22.56
$22.56
Volume
34,370
34,370
Avg. Vol
898,522
898,522
52-wk High
$23.96
$23.96
52-wk Low
$18.46
$18.46
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
David LaVance |
59 | 2011 | Independent Chairman of the Board |
John Cumming |
68 | 2013 | President, Chief Executive Officer |
Glenn Muir |
53 | 2008 | Chief Financial Officer, Executive Vice President - Finance & Administration, Director |
Jay Stein |
70 | 2008 | Chairman Emeritus, Senior Vice President & Chief Technical Officer |
Mark Casey |
49 | 2012 | Senior Vice President, Chief Administrative Officer, General Counsel, Secretary |
David Harding |
47 | 2010 | Senior Vice President, General Manager - International |
Rohan Hastie |
2013 | Senior Vice President, Group General Manager - Diagnostics | |
Peter Soltani |
52 | Senior Vice President, General Manager - Breast Health Line of Business | |
David Brady |
53 | 2003 | Senior Vice President - Human Resources |
Scott Garrett |
2013 | Director | |
Sally Crawford |
59 | 2007 | Independent Director |
Nancy Leaming |
66 | 2003 | Independent Director |
Lawrence Levy |
74 | 2005 | Independent Director |
Christiana Stamoulis |
42 | 2011 | Independent Director |
Elaine Ullian |
65 | 2007 | Independent Director |
Wayne Wilson |
64 | 2007 | Independent Director |
Deborah Gordon |
Vice President, Investor Relations |
Biographies
| Name | Description |
|---|---|
David LaVance |
Mr. David R. LaVance Jr., serves as an Independent Chairman of the Board of Hologic Inc. He has been one of Directors since December 2002 and served as Lead Independent Director from June 2008 until July 28, 2011 when he was appointed Chairman of the Board. Since June 2011, Mr. LaVance has served as the Chairman of the Board of Directors, CEO and President of Integrated Environmental Technologies, Ltd., a producer of antibacterial solutions and equipment that manufactures such solutions. Since 2003, Mr. LaVance has served as the Chairman of the Board of Directors, CEO and President of Scivanta Medical Corporation, a developer of specialized medical products with a focus on cardiac technologies. Since 1997, Mr. LaVance has served as President of Century Capital Associates LLC, an investment banking firm that he founded specializing in biosciences fields. |
John Cumming |
Mr. John W. Cumming has been appoint President, Chief Executive Officer of Hologic Inc., effective July 18, 2013. Mr. Cumming joined the Company in 2000 as the Senior Vice President and President of Lorad. In 2001, Mr. Cumming was promoted to Chief Executive Officer and appointed to the Board. Mr. Cumming served as Chief Executive Officer through 2009, and also served as President from 2001 until 2003 and Chairman of the Board from 2002 until 2007 and again from 2008 through 2011. From 2009 through 2011, Mr. Cumming served as Chairman and an executive officer focused on international and strategic development. Most recently, Mr. Cumming served as Global Strategic Advisor, a position he has held since 2011. Before joining Hologic, Mr. Cumming served as President and Managing Director of Health Care Markets Group, a strategic advisory and investment banking firm that he founded in 1984. |
Glenn Muir |
Mr. Glenn P. Muir is Chief Financial Officer, Executive Vice President - Finance & Administration, Director of Hologic Inc. He is a certified public accountant, was appointed to Board in July 2001, and has held the position of Executive Vice President, Finance and Administration since September 2000. Mr. Muir has been Chief Financial Officer since 1992. Mr. Muir served as the Company’s Controller from the time he joined the company in October 1988 through 1992. Mr. Muir received an M.B.A. from the Harvard Graduate School of Business Administration in 1986. As Executive Vice President and Chief Financial Officer, Mr. Muir is an integral member of senior management team, with experience in finance and financial reporting. In addition to serving as Chief Financial Officer, Mr. Muir is an active participant in the oversight of operations and formulation and implementation of strategic initiatives. |
Jay Stein |
Dr. Jay A. Stein is Chairman Emeritus, Senior Vice President and Chief Technical Officer of Hologic Inc. Dr. Stein, is a a co-founder of the Company, has served as Executive or Senior Vice President and Chief Technical Officer of the Company since its organization in October 1985. Since October 2007, Dr. Stein has served as Chairman Emeritus pursuant to which he continues to participate in meetings of the Board. He served as a director of the Company from October 1985 through October 2007, including as Chairman of the Company’s Board from June 2001 to November 2002. Dr. Stein received a Ph.D. in Physics from The Massachusetts Institute of Technology. He is the principal author of nineteen patents involving X-ray technology. |
Mark Casey |
Mr. Mark J. Casey is Senior Vice President, Chief Administrative Officer, General Counsel, Secretary of Hologic Inc. Mr. Casey joined in October 2007 in connection with the merger with Cytyc. In March 2012, Mr. Casey was appointed to the role of Chief Administrative Officer and now serves as the Senior Vice President, Chief Administrative Officer, General Counsel and Secretary. Prior to this, he was Senior Vice President and General Counsel. While at Cytyc, Mr. Casey was Vice President, Deputy General Counsel and Chief Patent Counsel. Prior to joining Cytyc in 2002, Mr. Casey served as an attorney for Boston Scientific from 1998-2002 and EMC Corporation from 1996-1998. Mr. Casey joined Digital Equipment Corporation’s (DEC) law department in 1992, where he served until 1996. Prior to this, Mr. Casey held various engineering positions with DEC and AT&T Network Systems from 1985 through 1992. Mr. Casey received a B.S. in Electrical Engineering from Syracuse University and a J.D. from Suffolk University. |
David Harding |
Mr. David P. Harding is Senior Vice President, General Manager - International of Hologic Inc. Mr. Harding joined in October 2007 in connection with merger with Cytyc. Mr. Harding is Senior Vice President and General Manager, International, a role he assumed in early 2010. Prior to this, he was Senior Vice President and General Manager of the Interventional Breast Solutions business. At the time of the merger with Cytyc, Mr. Harding was Senior Vice President and President, Cytyc International. From 1993 to 2004, Mr. Harding was an Associate and then Principal at McKinsey & Company, where he served as a strategy consultant in a variety of industries with a focus on sales and marketing management. Prior to McKinsey, Mr. Harding was in a variety of engineering roles at JAE Oregon and Rockwell International. Mr. Harding earned his MBA from the Wharton School of the University of Pennsylvania and his Bachelor of Science degree in Aerospace Engineering from the University of Southern California. |
Rohan Hastie |
Mr. Rohan Hastie has been appointed as Senior Vice President, Group General Manager - Diagnostics of Hologic Inc. effective January 22, 2013. He was formerly a vice president and general manager within the Women's Health group of the Company's Diagnostics segment. |
Peter Soltani |
Dr. Peter K. Soltani is Senior Vice President, General Manager - Breast Health Line of Business of Hologic Inc. Dr. Soltani joined in November 2000 as Vice President and General Manager of Direct Radiography Corp. and served as such until September 30, 2007, when he was appointed to manage Breast Health line of business. He currently serves as Senior Vice President and General Manger, Breast Health Line of Business. Prior to joining the Company, Dr. Soltani served as General Manager, NDT Business Group, Digital Systems at AGFA Corporation from 1999 to November 2000. From 1994 to 1999, Dr. Soltani served as General Manager, Imaging Systems Division of Liberty Technologies, a division of Crane Nuclear, Inc. Prior to joining Liberty Technologies, Dr. Soltani was with Quantex Corporation, serving as Vice President, Technology from 1992 to 1994, Director, Product Development from 1990 to 1992 and as a Senior Staff Scientist from 1986 to 1990. Dr. Soltani is the principal author or co-author of numerous patents related to digital imaging technologies and has published numerous articles on digital imaging. Dr. Soltani received a Ph.D. in Materials Engineering from the University of Maryland in 1994. |
David Brady |
Mr. David J. Brady is Senior Vice President - Human Resources of Hologic Inc. Mr. Brady joined the company in May 1995 as Manager, Human Resources and served as such until January 1998 when he was promoted to Director, Human Resources. Following this promotion in September 2000 he was promoted to Vice President, Human Resources & Facilities Administration. In February, 2003, Mr. Brady was appointed Senior Vice President, Human Resources. Prior to joining the Company Mr. Brady served as Manager of Human Resources at IPL Systems. |
Scott Garrett |
Mr. Scott T. Garrett has been appointed as Director of Hologic, Inc., effective May 8, 2013. Mr. Garrett is currently an Operating Partner at Water Street Healthcare Partners. Mr. Garrett joined Water Street in 2011 after approximately 35 years in the global healthcare industry. Prior to joining Water Street, Mr. Garrett served as Chairman, President and Chief Executive Officer of Beckman Coulter, from 2008 to 2011. Mr. Garrett joined Beckman Coulter in 2002 as President, Clinical Diagnostics Division. Prior to that, Mr. Garrett served as Vice Chairman and Interim Chief Executive Officer of Kendro Laboratory Products from 1999 to 2001. From 1994 to 1998, Mr. Garrett served as Chairman, President and Chief Executive Officer of Dade Behring. He began his career at American Hospital Supply Corporation and continued there after that company was acquired by Baxter International, ultimately serving as Chief Executive of Baxter’s global laboratory business, Baxter Diagnostics. Mr. Garrett received a B.S. in Mechanical Engineering from Valparaiso University and a M.B.A. from Lake Forest Graduate School of Management. Mr. Garrett currently also serves on the boards of directors of Immucor, Inc., MarketLab Inc., and AdvaMedDx. |
Sally Crawford |
Ms. Sally W. Crawford is an Independent Director of Hologic Inc. Ms. Crawford became one of directors effective upon merger with Cytyc Corporation (“Cytyc”) in October 2007, having previously served as a director of Cytyc since January 1998. From April 1985 until January 1997, Ms. Crawford served as Chief Operating Officer of Healthsource, Inc., a publicly held managed care organization headquartered in New Hampshire. During her tenure at Healthsource, Inc., Ms. Crawford held a variety of positions and responsibilities, including that company’s Northern Region operations and marketing efforts. Since January 1997, Ms. Crawford has been a health care consultant in New Hampshire. Ms. Crawford serves as a director of Universal American Corporation, Exact Sciences Corporation, Zalicus, Inc. and Insulet Corporation. Ms. Crawford served as a director of Chittenden Corporation from 1998 to 2008. |
Nancy Leaming |
Ms. Nancy L. Leaming is an Independent Director of Hologic Inc., since September 2003. Ms. Leaming, an independent consultant, was the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance, from 2003 to 2005. Prior to that, Ms. Leaming served as Tufts Health Plan’s President and Chief Operating Officer from 1998 to 2003, the Chief Operating Officer from 1995 to 1998 and the Chief Operating Officer/Chief Financial Officer from 1986 to 1995. Ms. Leaming currently serves as a director of the Board of Edgewater Technology, Inc. and Biogen Idec, Inc. |
Lawrence Levy |
Mr. Lawrence M. Levy is an Independent Director of Hologic Inc., since December 13, 2005. Mr. Levy retired from the position of Senior Counsel at Brown Rudnick LLP, an international law firm, in January 2011. Mr. Levy had been Senior Counsel at Brown Rudnick since February 2005 and, for more than 30 years before that had been a Partner at the firm, specializing in Corporate and Securities Law. Mr. Levy served as Secretary from formation in 1985 until December 2005. Mr. Levy is also a director of Option N.V. of Belgium, Scivanta Medical Corporation and the Facing History and Ourselves National Foundation. Mr. Levy received a B.A. from Yale University and a LLB from Harvard Law School. Mr. Levy is a seasoned corporate attorney with experience in representing public and private companies in the United States and abroad. Mr. Levy chaired Brown Rudnick’s International Practice Group and, in 1997, opened Brown Rudnick’s London office, dividing his time between the firm’s London and Boston offices for more than 13 years. |
Christiana Stamoulis |
Ms. Christiana Stamoulis serves as an Independent Director of Hologic, Inc., since November 1, 2011. Ms. Stamoulis currently serves as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals Incorporated. Ms. Stamoulis joined Vertex in 2009 with approximately 15 years of experience in the financial services and management consulting industries where she advised global pharmaceutical and biotechnology companies on strategic and corporate finance decisions. Prior to joining Vertex, she was a Managing Director in the Investment Banking division of Citigroup from 2006 to 2009 where she led the building of the firm’s U.S. Life Sciences investment banking practice. Prior to her role at Citigroup, she was at Goldman, Sachs & Co. where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis holds a Bachelor of Science degree in Economics and a Bachelor of Science degree in Architecture from the Massachusetts Institute of Technology (MIT). Additionally, she holds a Master of Business Administration from the MIT Sloan School of Management where she focused on Applied Economics and Finance. |
Elaine Ullian |
Mrs. Elaine S. Ullian is an Independent Director of Hologic Inc., since October 22, 2007. Ms. Ullian served as President and Chief Executive Officer of Boston Medical Center, the successor of Boston University Medical Center Hospital from 1996 until her retirement in January 2010. In April 1994, Mrs. Ullian was appointed President and Chief Executive Officer of Boston University Medical Center Hospital. From January 1987 to March 1994, Mrs. Ullian held the position of President and Chief Executive Officer of Faulkner Corporation/Faulkner Hospital. She holds two academic appointments: Associate Professor at Boston University School of Medicine and lecturer at Harvard University School of Public Health. Mrs. Ullian also serves as a director of Vertex Pharmaceuticals Incorporated and Thermo Fisher Scientific Inc. Mrs. Ullian previously served as one of directors from 1996 to 2003 and served as a director of Valeant Pharmaceuticals International, Inc. from 2004 to 2008. In her professional capacity as former Chief Executive Officer/President of 3 hospitals, including two academic medical centers, Mrs. Ullian brings knowledge and understanding of Hologic’s customer base, their priorities and challenges especially under Health Care Reform. All 3 institutions led by Mrs. Ullian over a 25 year period had a commitment to accessible health care, and a particular focus on women’s health services. |
Wayne Wilson |
Mr. Wayne Wilson is an Independent Director of Hologic Inc. Mr. Wilson became one of directors effective upon merger with Cytyc in October 2007, having previously served as a director of Cytyc since 2003. Mr. Wilson has been an independent business advisor since 2002. From 1995 to 2002, Mr. Wilson served in various roles, including as President, Chief Operating Officer, and Chief Financial Officer, at PC Connection, Inc., a Fortune 1000, direct marketer of information technology products and services. From 1986 to 1995, he was a partner in the assurance and advisory services practice of Deloitte & Touche LLP. Mr. Wilson also serves as a director of ARIAD Pharmaceuticals, Inc., Edgewater Technology, Inc. and FairPoint Communications, Inc. |
Deborah Gordon |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
David LaVance |
-- |
John Cumming |
3,879,600 |
Glenn Muir |
2,149,620 |
Jay Stein |
1,590,100 |
Mark Casey |
1,224,850 |
David Harding |
1,151,090 |
Rohan Hastie |
-- |
Peter Soltani |
1,046,530 |
David Brady |
-- |
Scott Garrett |
-- |
Sally Crawford |
-- |
Nancy Leaming |
-- |
Lawrence Levy |
-- |
Christiana Stamoulis |
-- |
Elaine Ullian |
-- |
Wayne Wilson |
-- |
Deborah Gordon |
-- |
As Of 28 Sep 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
David LaVance |
0 | 0 |
John Cumming |
1,107,500 | 32,645,660 |
Glenn Muir |
1,098,416 | 29,536,250 |
Jay Stein |
35,000 | 1,062,600 |
Mark Casey |
10,416 | 2,969 |
David Harding |
96,086 | 101,460 |
Rohan Hastie |
0 | 0 |
Peter Soltani |
206,808 | 883,333 |
David Brady |
0 | 0 |
Scott Garrett |
0 | 0 |
Sally Crawford |
0 | 0 |
Nancy Leaming |
0 | 0 |
Lawrence Levy |
0 | 0 |
Christiana Stamoulis |
0 | 0 |
Elaine Ullian |
0 | 0 |
Wayne Wilson |
0 | 0 |
Deborah Gordon |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LAVALLEE ROBERT H |
11,254 | $20.89 |
MUIR GLENN P |
28,000 | $19.78 |
MUIR GLENN P |
28,000 | $3.56 |
CASCELLA ROBERTO A |
20,000 | $19.55 |
CASCELLA ROBERTO A |
20,000 | $3.56 |
SOLTANI PETER K |
14,079 | $19.30 |
HARDING DAVID P |
10,866 | $19.30 |
LAVALLEE ROBERT H |
5,413 | $19.30 |
CASEY MARK J |
9,200 | $19.30 |
MUIR GLENN P |
28,000 | $21.42 |
MUIR GLENN P |
28,000 | $3.56 |
CASCELLA ROBERTO A |
20,000 | $20.71 |
CASCELLA ROBERTO A |
20,000 | $3.56 |
GARRETT SCOTT T |
8,603 | $0.00 |
LAVANCE DAVID R JR |
12,774 | $22.12 |
LAVANCE DAVID R JR |
4,997 | $22.12 |
LAVANCE DAVID R JR |
12,774 | $18.82 |
SOLTANI PETER K |
12,000 | $13.63 |
SOLTANI PETER K |
24,729 | $15.75 |
SOLTANI PETER K |
20,000 | $13.87 |
SOLTANI PETER K |
12,000 | $22.02 |
SOLTANI PETER K |
32,000 | $22.05 |
SOLTANI PETER K |
32,000 | $14.50 |
SOLTANI PETER K |
24,729 | $22.05 |
SOLTANI PETER K |
20,000 | $22.05 |

